Financial News
Press Releases about Astrazeneca Plc ADR
![](https://mms.businesswire.com/media/20220316005688/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220221005258/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220214005718/en/1359067/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220124005039/en/484259/5/Logo.jpg)
Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis
January 24, 2022
From AstraZeneca
Via Business Wire
![](https://mms.businesswire.com/media/20220118006249/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220118006248/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220117005097/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220117005097/en/484259/5/Logo.jpg)
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019
January 14, 2022
Topics
Death
Exposures
Death
![](https://mms.businesswire.com/media/20220113005318/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220113005298/en/484259/5/Logo.jpg)
From AstraZeneca
Via Business Wire
![](https://mms.businesswire.com/media/20211223005099/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20211216005736/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20211212005048/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20211209005708/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20211208006139/en/930407/5/EVUS_TM_Prom_RGB_FC_Pos.jpg)
![](https://mms.businesswire.com/media/20211203005080/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20211130005457/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20211118005506/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20211117006015/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20211105005227/en/484259/5/Logo.jpg)
From AstraZeneca
Via Business Wire
![](https://mms.businesswire.com/media/20211101005708/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20211101005061/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20211025005799/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20211020005098/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20211015005143/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20211008005144/en/484259/5/Logo.jpg)
From AstraZeneca
Via Business Wire
![](https://mms.businesswire.com/media/20211005005414/en/484259/5/Logo.jpg)
AZD7442 Request for Emergency Use Authorization for COVID-19 Prophylaxis Filed in US
October 05, 2021
From AstraZeneca
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.